News

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

LG Chem to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its T-cell therapy candidates…

2 years ago

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to List on the Nasdaq Following Business Combination with Social Capital Suvretta Holdings Corp. III

ProKidney Class A ordinary shares to begin trading on Nasdaq under the ticker symbol “PROK” on July 12, 2022ProKidney receives…

2 years ago

Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug

Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc.,…

2 years ago

Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022

PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that…

2 years ago

Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022

WOBURN, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of…

2 years ago

Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu

Partnership aims to expand the Transfusion Transmissible Infections, other Infectious Diseases, and clinical diagnostics assay menu on Quotient’s multimodality, multiplexed…

2 years ago

CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal

MONTREAL, July 12, 2022 (GLOBE NEWSWIRE) -- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies today announced close to CAN…

2 years ago

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022…

2 years ago

Aurora Spine Announces New FDA indication clearance of Lumbar Spinal Stenosis for its ZIP™ series of MIS implants

CARLSBAD, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),…

2 years ago

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy™

-- Training for physical therapists treating patients with multiple sclerosis (MS) is now available on demand --NEWTOWN, Pa., July 12,…

2 years ago